





Objective: To examine the effect of niacin on the progression of carotid intima-media 
thickness (IMT) in patients with high level of lipoprotein (Lp) (a).
Methods: Patients at low-density lipoprotein-cholesterol goal but with Lp (a) >25 mg/dL 
and mean carotid IMT >0.75 mm were included. Eligible patients were randomized at a 1:2 
ratio into one of two groups for 24 months: control or 1,500 mg extended release niacin. The 
primary study outcomes were the percentage changes in mean and maximal carotid IMT. The 
percentage change in lipid profiles including Lp (a) was analyzed as a secondary study outcome.
Results: Among 96 randomized patients, 31 completed the study (mean age: 65 years; male: 
44%). At follow-up, the percentage change in mean carotid IMT was not significantly different 
between the two groups (−1.4%±15.5% and −1.1%±7.3% in the control and niacin groups, 
respectively, p=0.95). The percentage change in maximal carotid IMT was also similar in the 
two groups (0.7%±16.5% and −4.4%±11.6%, respectively, p=0.35). Elevation of high-density 
lipoprotein-cholesterol tended to be higher in the niacin group (p=0.07), and there was a 
significant difference in the percentage change in hemoglobin A1c between the two groups 
(−1.9%±2.2% and 3.3%±6.7%, respectively, p=0.02). Reduction of Lp (a) was greater in the 
niacin-treated group compared to placebo, but the difference was not statistically significant.
Conclusion: Treatment with niacin for two years did not inhibit the progression of carotid 
intima-media thickening in patients with high Lp (a) level. However, this study may have 
been underpowered to evaluate the primary study outcome.
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INTRODUCTION
Previous studies, including the Familial Atherosclerosis Treatment Study, HDL-
Atherosclerosis Treatment Study, Armed Forces Regression Study, Carotid Plaque 
Composition by MRI during Lipid-Lowering Study, and Arterial Biology for the Investigation 
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of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in 
Atherosclerosis Trial (ARBITER 6-HALTS), have reported that niacin slows progression of 
coronary artery stenosis1 and carotid intima-media thickness (IMT).2,3 However, analyses 
synthesizing both old and new studies now suggest that niacin is unlikely to be effective in 
reducing clinical events in people with high cardiovascular risk.4-8
Elevated lipoprotein (Lp) (a) is an independent risk factor of cardiovascular disease in 
patients with diabetes mellitus who also commonly have atherogenic dyslipidemia beyond 
hyper low-density lipoprotein (LDL)-cholesterolemia.9 Additionally, Lp (a) is known to 
contribute to residual cardiovascular risk in a subset of patients who are able to achieve 
optimal level of LDL-cholesterol (LDL-C).10 Furthermore, it has been reported that Lp (a) may 
contribute to the progression of aortic stenosis.11 A recent study also demonstrated that Lp (a) 
induces monocyte trafficking in the arterial wall.12
The use of niacin to control Lp (a) is well known, especially in Korea.13 A prior study reported 
that niacin decreases the production of apolipoprotein (a) and Lp (a)-apoB-100. Likewise, 
niacin regulates lipid levels by reducing the production of very LDL.14 Nevertheless, no 
clinical trial has analyzed the effects of niacin pharmacotherapy on Lp (a) level, clinical 
outcomes, or surrogate markers.15
The aim of this study was to examine the effect of niacin on the progression of carotid 
intima-media thickening in patients at LDL-C goal but high Lp (a) level. Specifically, we 
hypothesized that the effect of niacin on Lp (a) could partially inhibit vascular changes in a 
population with residual cardiovascular risk.
MATERIALS AND METHODS
1. Study population
Written informed consent was obtained from all study participants. Patients who visited the 
outpatient clinic of the Division of Cardiology, Severance Hospital during the study period 
were initially screened. The inclusion criteria were age 20–79 years, at LDL-C goal as defined 
by National Cholesterol Education Program Adult Treatment Panel III guidelines,16 Lp (a) 
level >25 mg/dL, and mean carotid IMT >0.75 mm. Patients who met all inclusion criteria 
were enrolled in the study. Individuals were eligible regardless of whether they were taking 
lipid-lowering medication. The exclusion criteria were history of acute coronary syndrome 
or cerebrovascular accident within three months prior to study enrollment, uncontrolled 
hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), 
or diabetes mellitus (hemoglobin A1c >9%).We also excluded patients with a history of an 
acute or chronic systemic inflammatory disease, malignancy, chronic endocrine-, hepatic-, 
or renal disease; patients who were pregnant or breast feeding, actively using hormone 
replacement therapy, or who had a history of niacin intolerance.
2. Study protocol
The Institutional Review Board of Severance Hospital, Seoul, Korea, approved this study 
(4-2008-3530). This was a 24-month, open-label, randomized study. At the screening visit, 
each patient was interviewed about medical history and underwent physical examination, 
laboratory assessment, and carotid ultrasound. Patients who met the inclusion criteria were 
randomized at a 1:2 ratio into one of 2 groups for 24 months: control or niacin extended 
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release 1,500 mg (Exlip; Seoul Pharma, Seoul, Korea). We selected a 2:1 randomization 
ratio in anticipation of a higher number of adverse events (AEs) and discontinuation in the 
niacin group. We also used an extended release niacin, which has a better tolerance for 
flushing than other niacin formulations. Furthermore, extended release niacin was the only 
formulation of niacin available in Korea at the time the study was performed. In the treatment 
group, the initial dose of niacin was 500 mg/day, which was sequentially increased at the 
beginning of weeks 5 (1,000 mg/day) and 9 (1,500 mg/day). The final dose was continued to 
the end of the study (Fig. 1). Patients were enrolled between March 2012 and November 2014, 
and a total of 96 patients was randomized.
Blood samples were collected at the time of randomization and at 24 months of treatment. 
Patients were instructed to fast and avoid alcohol and smoking for at least 12 hours prior to 
sampling. Samples were analyzed within 4 hours by the local laboratory, which was certified 
by the Korean Society of Laboratory Medicine. Levels of total cholesterol, triglycerides (TG), 
and high-density lipoprotein-cholesterol (HDL-C) were measured by enzymatic methods 
using a Hitachi 7600-120 chemistry analyzer (Hitachi, Tokyo, Japan). LDL-C was calculated 
using the Friedwald formula. Lp (a) was measured by rate nephelometry (IMMAGE system; 
Beckman Coulter, Brea, CA, USA). Tolerability for the treatment was assessed by history 
taking and physical examination.
3. Carotid ultrasound
High-resolution carotid ultrasound was performed at baseline and after 24 months according 
to a standard protocol by 2 trained sonographers. The exam was performed using commercially 
available equipment (Acuson X300; Siemens Healthineers, Erlangen, Germany) with a 7.5-
MHz linear transducer. B-mode images of the far wall of the distal right and left common 
carotid arteries were captured at the end-diastolic period. Carotid IMT was measured by a 
single trained reader in a 1-cm segment from 1 cm proximal to the carotid bifurcation using an 
automated system. IMT values for each side were averaged and used in all analyses. The intra-
observer and inter-observer coefficients of variation were 5.4% and 6.4%, respectively.
4. Statistical analysis
The primary study outcomes were the percentage changes in mean and maximal carotid 
IMTs from time of randomization to 24 months of treatment. The percentage changes in 
total cholesterol, TG, HDL-C, LDL-C, non-HDL-C, and Lp (a) were evaluated as secondary 
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outcome variables. Outcome variables were evaluated by per protocol analysis. A minimum 
of 25 and 50 participants were planned for the control and niacin groups, respectively, 
assuming a power of 0.80 and a significance level of 0.05 to demonstrate superiority of niacin 
over control. A 3% difference in the percentage change of mean carotid IMT with a standard 
deviation of 3.8% between the two groups was predefined as significant. To compensate for 
an anticipated drop-out rate of 20%, we aimed to enroll at least 30 and 60 participants in 
the placebo and niacin groups, respectively. Group differences in categorical variables were 
assessed using Fisher's exact test. Student's t-test was used to compare the mean values of 
continuous variables between the two groups. Paired t-test was used to assess differences 
in parameters before and after treatment within each group. Differences were considered 
significant if the p-value was <0.05. All analyses were performed using SPSS version 17.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
1. Patient characteristics
Among 96 randomized patients, 31 (18 of 33 in the control group and 13 of 63 in the niacin 
group) completed the study. A total of 65 patients dropped from the study and was excluded 
from efficacy analysis, with 42 due to AEs, 15 due to withdrawal of consent, and eight due 
to protocol violation. The clinical characteristics of the patients who were randomized and 
completed the study are listed in Table 1. The mean age of randomized patients was 65 years, 
and 44% were male. The rates of diabetes mellitus, coronary artery disease (CAD), and statin-
use were 13%, 32%, and 48%, respectively. The mean carotid IMT was 0.822±0.192 mm. Among 
the 31 patients who completed the study, there was a higher proportion of males, and the mean 
age and prevalence of CAD were lower in the niacin group. However, none of the clinical or 
laboratory variables were significantly different between the two groups.
61https://doi.org/10.12997/jla.2019.8.1.58
Niacin in patients with elevated Lp (a)
https://e-jla.org
Table 1. Characteristics of study subjects
Subjects who were randomized (n=96) Subjects who completed the study (n=31)
Control (n=33) Niacin (n=63) p Control (n=18) Niacin (n=13) p
Male 11 (33) 31 (49) 0.13 8 (44) 11 (85) 0.02
Age (yr) 65±8 64±8 0.50 65±6 60±7 0.02
Hypertension 23 (70) 50 (79) 0.30 24 (77) 12 (92) 0.07
DM 4 (12) 8 (13) 0.94 3 (17) 2 (15) 0.93
Smoking 4 (12) 17 (27) 0.27 3 (17) 6 (46) 0.29
CAD 13 (39) 18 (29) 0.29 10 (56) 2 (15) 0.02
BMI (kg/m2) 24.5±5.9 25.0±3.1 0.58 24.3±7.7 25.7±2.7 0.54
Laboratory values (mg/dL)
TC 177±25 177±31 0.98 176±29 166±24 0.32
TG 118 (91–143) 108 (77–156) 0.52 104 (87–128) 108 (87–135) 0.49
HDL-C 48.8±9.9 50.1±12.1 0.59 51.7±11.9 44.6±11.7 0.11
LDL-C 104±21 102±22 0.71 100±21 101±22 0.88
Non-HDL-C 129±23 128±27 0.79 124±22 121±23 0.72
Lp (a) 59.9±28.5 64.3±39.9 0.53 61.6±31.8 72.2±32.0 0.37
Glucose 105±11 103±14 0.45 106±12 104±15 0.71
HbA1c 4.08±0.45 6.07±0.63 0.97 6.07±0.37 5.93±0.50 0.38
Carotid IMT (mm)
Mean 0.837±0.244 0.814±0.159 0.58 0.877±0.288 0.779±0.146 0.27
Maximal 1.099±0.276 1.084±0.229 0.79 1.142±0.323 1.076±0.243 0.55
Statin use 16 (48) 40 (63) 0.26 12 (67) 9 (69) 0.89
Values are presented as number (%), mean±standard deviation, or median (interquartile range).
DM, diabetes mellitus; CAD, coronary artery disease; BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; 




2. Changes in primary and secondary outcomes
At the 24-month follow-up, percentage change in mean carotid IMT was not significantly 
different between the 2 groups (−1.4%±15.5% and −1.1%±7.3% in the control and niacin 
groups, respectively, p=0.95). The maximal carotid IMT did decrease in the niacin group 
compared to before treatment, but the difference was not significant (p=0.07). Likewise, the 
overall percentage change was similar for the two groups (0.7%±16.5% and −4.4%±11.6%, 
respectively, p=0.35) (Table 2).
At follow-up, HDL-C was significantly elevated in the niacin group (p=0.03), and 
hemoglobin A1c was decreased in the control group (p=0.02). None of the other parameters 
were significantly changed between the two groups. Although Lp (a) level decreased by 
−21.4%±35.6% in the niacin group, the difference was not statistically significant. Elevation 
of HDL-C tended to be greater in the niacin group (2.8%±13.3% and 13.2%±17.6%, in the 
control and niacin group, respectively, p=0.07), while the percentage change in hemoglobin 
A1c was significantly different between the two groups (−1.9%±2.2% and 3.3%±6.7%, 
respectively, p=0.02) (Table 3).
3. AEs
Forty-two patients experienced AEs during the study period and discontinued niacin as 
a result (Table 4). The most common AEs were skin-related and included complaints of 
pruritus, urticaria, and flushing (n=29, 69%). The second most common AEs were related 
to gastrointestinal complaints. Other less frequent AEs included chest symptoms and 
hyperglycemia.
DISCUSSION
To the best of our knowledge, this is the first study to examine the effect of niacin specifically 
in patients with elevated Lp (a) level. We found that treatment with niacin for two years in 
this patient population had a neutral effect on mean and maximal carotid IMT. Compared 
to the control group, the group treated with niacin exhibited significant change in glucose 
metabolism and marginal change in HDL-C level. Lp (a) was decreased to a greater extent 
after niacin treatment, but the difference was not significant.
Previous studies have shown that niacin does not reduce cardiovascular risk even though it 
improves multiple lipid parameters including Lp (a). However, existing studies pertaining to 
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Table 2. Changes of primary outcome variables (n=31)
Control (n=18) Niacin (n=13) p*
Mean carotid IMT
Before 0.877±0.287 0.779±0.146 0.27
After 0.837±0.216 0.770±0.151 0.33
% change −1.4±15.5 −1.1±7.3 0.95
p† 0.95 0.38
Maximal carotid IMT
Before 1.141±0.322 1.076±0.243 0.55
After 1.115±0.236 1.011±0.162 0.18
% change 0.7±16.5 −4.4±11.6 0.35
p† 0.89 0.07
Values are presented as mean±standard deviation.
IMT, intima-media thickness.




associations between niacin, Lp (a), and cardiovascular results did not use pre-determined 
endpoints.17 Although we hypothesized that niacin would inhibit thickening of carotid IMT in 
individuals with high Lp (a), we were unable to find evidence for such an effect. Our results 
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Table 3. Changes of secondary outcome variables (n=31)
Control (n=18) Niacin (n=13) p*
TC
Before 176±29 166±24 0.32
After 176±28 153±31 0.043
% change 0.5±10.1 −5.7±23.9 0.39
p† 0.96 0.28
TG
Before 104 (87–128) 108 (87–135) 0.49
After 94 (78–148) 98 (60–128) 0.56
% change 10±46 −3.1±52.6 0.46
p† 0.52 0.46
HDL-C
Before 51.7±11.9 44.6±11.7 0.11
After 52.7±11.2 50.3±14.6 0.62
% change 2.8±13.3 13.2±17.6 0.07
p† 0.74 0.03
LDL-C
Before 100±21 101±22 0.88
After 101±22 93±27 0.053
% change −9.0±21.3 −24.8±32.0 0.11
p† 0.70 0.11
Non-HDL-C
Before 124±22 121±23 0.72
After 123±22 103±28 0.03
% change −0.1±13.7 −12.1±28.5 0.18
p† 0.76 0.10
Lp (a)
Before 65.2±32.6 72.9±28.6 0.52
After 63.2±35.7 61.0±47.6 0.89
% change −3.2±20.2 −21.4±35.6 0.14
p† 0.41 0.23
HbA1c
Before 6.07±0.37 5.93±0.50 0.38
After 6.00±0.39 6.15±0.74 0.47
% change −1.9±2.2 3.3±6.7 0.02
p† 0.02 0.12
Values are presented as mean±standard deviation, or median (interquartile range).
TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density 
lipoprotein-cholesterol; Lp (a), lipoprotein (a); HbA1c, hemoglobin A1c.
*Comparison before and after treatment; †Comparison between two groups.
Table 4. Discontinuation of niacin due to adverse events over the study period
Numbers
Total AEs 42
Pruritus, urticaria, or flushing 29
Epigastric discomfort or nausea 3












are also in contrast to the ARBITER 6-HALTS study, which demonstrated regression of carotid 
IMT after niacin therapy.3 Although that study included populations of similar age to our study, 
there were differences in baseline LDL-C and carotid IMT, being higher and slightly lower 
compared to our patients, respectively. It remains uncertain which of the two study populations 
had a greater baseline cardiovascular risk and the extent to which that influenced the study 
outcomes. The reason for the discrepancy between the negative results of our trial and those 
of the ARBITER 6-HALTS study are not completely understood. The follow-up duration of our 
study was 24 months, 10 months longer than that of the ARBITER 6-HALTS study, making an 
insufficient treatment duration an unlikely explanation for the difference in results and lack 
of efficacy of niacin in our study. Because the inclusion criteria were difficult to meet and the 
discontinuation rate was high due to drug AEs, we also considered the possibility that the 
number of subjects who completed the study was insufficient to show a significant difference. 
Although niacin tended to decrease Lp (a) in our study, the standard deviation of the value 
was quite large, suggesting that there was considerable individual variation in the response to 
niacin therapy. Another possibility is that there may be no beneficial effect of niacin on carotid 
arteries. Indeed, no studies have demonstrated an association between pharmacologically 
increased level of HDL-C and reduction in cardiovascular outcomes.18 In addition, another 
study reported that niacin does not improve endothelial function in statins despite further 
improvement of lipid profiles.19 In recent studies, the effect of niacin on HDL functionality 
has been variable and not always beneficial.20 Although niacin significantly increases HDL-C 
level, it does not improve ABCA1-specific cholesterol efflux and has insufficient effects on the 
atheroprotective population of HDL.21
Our study population was selected on the basis of Lp (a) level, but not TG or HDL-C level. 
In contrast to our hypothesis, there may be a better candidate population for niacin therapy 
than individuals with high Lp (a) level. For example, patients with residual cardiovascular risk 
with high TG and low HDL-C levels might be better suited for niacin therapy. “Atherogenic 
dyslipidemia” includes a wide spectrum of lipid profiles, from hypertriglyceridemia, low 
HDL-C, qualitative changes of LDL, and elevated remnant lipoprotein levels. Individuals with 
these conditions may have high residual risk even if they have achieved the LDL-C target, 
and they may also gain benefit from additive lipid modifying therapy.22 In support of this 
possibility, a prior study demonstrated greater beneficial effects of niacin on endothelial cells 
in patients with low HDL-C.23
There were several potential limitations to the present study that should be considered when 
interpreting our results. First, as mentioned above, the drop-out rate was relatively high, 
and the number of patients who completed the study may have been insufficient to derive 
solid conclusions. Second, we used carotid IMTs as the primary study outcome. However, 
more recent international guidelines have suggested against routine measurement of carotid 
IMT for the purposes of risk stratification.24 Therefore, the decreasing clinical relevance of 
target variables in our study is another limitation of our study. Finally, the beneficial effect 
of niacin tends to be smaller in Chinese subjects compared to Europeans, according to the 
Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events 
(HPS2-THRIVE) study.5 Therefore, caution should be used when applying our results to 
other ethnicities.
In conclusion, a two-year treatment with niacin 1,500 mg/day did not block progression 
of carotid intimal-medial thickening in patients at LDL-C goal and high Lp (a). Although 
niacin induced metabolic changes to lipids and glucose, it did not have a significant effect 
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on the carotid arteries. However, due to suboptimal sample size, these results may have been 
underpowered to provide a solid conclusion.
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